ALX ONCOLOGY HOLDINGS INC
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
ALXO$1.11-13.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of December 31, 2022 | 40,861,386 | $41 | $589,735 | $(845) | $(325,467) | $263,464 |
| Issuance of common stock and pre-funded warrants in connection with equity offerings, net of underwriter discounts ($3,795) and issuance costs ($567) | 8,663,793 | 9 | 58,878 | — | — | 58,887 |
| Issuance of common stock under equity incentive plans | 344,213 | — | 269 | — | — | 269 |
| Issuance of common stock under employee stock purchase plan | 82,597 | — | 523 | — | — | 523 |
| Stock-based compensation | — | — | 26,273 | — | — | 26,273 |
| Unrealized gain on available-for-sale investments | — | — | — | 1,101 | — | 1,101 |
| Net loss | — | — | — | — | (160,805) | (160,805) |
| Balance as of December 31, 2023 | 49,951,989 | 50 | 675,678 | 256 | (486,272) | 189,712 |
| Issuance of common stock under equity incentive plans | 810,243 | 1 | 1,631 | — | — | 1,632 |
| Issuance of common stock under employee stock purchase plan | 91,138 | — | 351 | — | — | 351 |
| Issuance of common stock through ATM offering, net of commissions ($839) | 2,199,542 | 2 | 29,659 | — | — | 29,661 |
| Stock-based compensation | — | — | 27,093 | — | — | 27,093 |
| Unrealized gain on available-for-sale investments | — | — | — | 19 | — | 19 |
| Net loss | — | — | — | — | (134,850) | (134,850) |
| Balance as of December 31, 2024 | 53,052,912 | 53 | 734,412 | 275 | (621,122) | 113,618 |
| Issuance of common stock under equity incentive plans | 294,454 | — | 14 | — | — | 14 |
| Issuance of common stock under employee stock purchase plan | 64,517 | — | 24 | — | — | 24 |
| Issuance of common stock through ATM offering, net of commissions ($37) | 976,139 | 1 | 1,687 | — | — | 1,688 |
| Stock-based compensation | — | — | 12,579 | — | — | 12,579 |
| Unrealized loss on available-for-sale investments | — | — | — | (247) | — | (247) |
| Net loss | — | — | — | — | (101,695) | (101,695) |
| Balance as of December 31, 2025 | 54,388,022 | $54 | $748,716 | $28 | $(722,817) | $25,981 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.